Translating NIA-AA criteria into usual practice: Report from the ReDeMa Project.

Autor: Sánchez-Soblechero A; Neurology Service University Hospital Gregorio Marañón Madrid Spain., Berbel A; Neurology Service Cruz Roja Hospital Madrid Spain., Villarejo A; Neurology Service University Hospital 12 de Octubre Madrid Spain., Palmí-Cortés I; Neurology Service University Hospital Infanta Sofía, San Sebastián de los Reyes Madrid Spain., Vieira A; Neurology Service University Hospital la Princesa Madrid Spain., Gil-Moreno MJ; Neurology Service Torrejón University Hospital Madrid Spain., Fernández C; Neurology Service University Hospital Sanitas La Moraleja Madrid Spain., Martín-Montes Ã; Hospital La Paz Institute for Health Research - IdiPAZ (La Paz University Hospital - Universidad Autónoma de Madrid) Madrid Spain., Carreras MT; Neurology Service University Hospital la Princesa Madrid Spain., Fernández Y; Memory Disorders Clinic - HM Hospitals and Neurology Service - University Hospital Gregorio Marañón Madrid Spain., Puertas C; Clinical Biochemistry Service University Hospital Gregorio Marañón Madrid Spain., Blanco-Palmero V; Neurology Service University Hospital 12 de Octubre Madrid Spain., Llamas S; Neurology Service University Hospital 12 de Octubre Madrid Spain., González-Sánchez M; Neurology Service University Hospital 12 de Octubre Madrid Spain.; Group of Neurodegenerative Diseases University Hospital 12 de Octubre Research Institute (imas12), and Biomedical Research Networking Center in Neurodegenerative Diseases (CIBERNED) Madrid Spain., Lapeña T; Neurology Service Cruz Roja Hospital Madrid Spain., de Luis P; Neurology Service HM Hospitals Madrid Spain., Manzano S; Neurology Service Infanta Leonor University Hospital Madrid Spain., Olazarán J; Memory Disorders Clinic - HM Hospitals Neurology Service - University Hospital Gregorio Marañón, and Maria Wolff Foundation Madrid Spain.
Jazyk: angličtina
Zdroj: Alzheimer's & dementia (New York, N. Y.) [Alzheimers Dement (N Y)] 2024 Mar 18; Vol. 10 (1), pp. e12451. Date of Electronic Publication: 2024 Mar 18 (Print Publication: 2024).
DOI: 10.1002/trc2.12451
Abstrakt: Introduction: Biomarker-informed criteria were proposed for the diagnosis of Alzheimer's disease (AD) by the National Institute on Aging and the Alzheimer's Association (NIA-AA) in 2011; however, the adequacy of this criteria has not been sufficiently evaluated.
Methods: ReDeMa ( Red de Demencias de Madrid ) is a regional cohort of patients attending memory and neurology clinics. Core cerebrospinal fluid biomarkers were obtained, NIA-AA diagnostic criteria were considered, and changes in diagnosis and management were evaluated.
Results: A total of 233 patients were analyzed (mean age 70 years, 50% women, 73% AD). The diagnostic language was modified significantly, with a majority assumption of NIA-AA definitions (69%). Confidence in diagnosis increased from 70% to 92% ( p < 0.0005) and management was changed in 71% of patient/caregivers. The influence of neurologist's age or expertise on study results was minimal.
Discussion: The NIA-AA criteria are adequate and utile for usual practice in memory and neurology clinics, improving diagnostic confidence and significantly modifying patient management.
Highlights: Alzheimer's disease (AD) cerebrospinal fluid (CSF) biomarkers increase diagnostic certainty regardless of the neurologist.AD CSF biomarkers lead to changes in disease management .Biomarker-enriched, 2011 NIA-AA diagnostic criteria are adequate for usual practice.
Competing Interests: Authors declare no conflicts of interest in relation to this study. Author disclosures are available in the Supporting Information.
(© 2024 The Authors. Alzheimer's & Dementia: Translational Research & Clinical Interventions published by Wiley Periodicals LLC on behalf of Alzheimer's Association.)
Databáze: MEDLINE
Externí odkaz: